Turning to Broad Sequencing Panels for Targeted Therapy in Advanced NSCLC
Mohammad Razaq, MD, discusses how the detection of driver mutations has changed the way treatment is approached in advanced non–small cell lung cancer.
More From BioPortfolio on "Turning to Broad Sequencing Panels for Targeted Therapy in Advanced NSCLC"